Market Overview

Piper Jaffray On FDA Approval Of Insys Therapeutics' Anorexia Drug Syndros

Piper Jaffray On FDA Approval Of Insys Therapeutics' Anorexia Drug Syndros
Related INSY
Wonder Women Of Weed: Jodie Emery, The Entrepreneurial Rebel With A Cause
Former Mexican President Vicente Fox Talks NAFTA, Trump And Regulated Marijuana Trade
INSYS Therapeutics (INSY) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow (Seeking Alpha)

Insys Therapeutics Inc (NASDAQ: INSY) announced the FDA approval of Syndros, and is waiting on a controlled substance designation from the Drug Enforcement Agency [DEA]. Piper Jaffray’s David Amsellem reiterated an Overweight rating on the company, with a price target of $28.

Syndros is an oral solution of dronabinol, or the cannabinoid THC, and received FDA approval for anorexia associated with weight loss in patients with AIDS, and chemotherapy-induced nausea and vomiting in patients who have failed conventional anti-emetics.

Thoughts On DEA And Commercial Impact

Management had previously indicated that it expected a schedule II controlled substance designation for Syndros. “Recall that Marinol has a less restrictive schedule III designation, meaning that prescribers can write up to 5 refills (whereas no refills are permitted for a schedule II product),” analyst David Amsellem wrote.

Related Link: Insys Therapeutics +20% Premarket @$16.25; Co Announced FDA Approval of Syndros

The analyst believes a schedule II designation would not have a major commercial impact, since patients in these settings typically use dronabinol on an as-needed basis. The impact would have been higher if this were a chronic use product. Moreover, physicians in oncology supportive care are well-versed in prescribing schedule II products.

“Given these dynamics, and the fact that the product has meaningful differentiation vs. its predecessor (i.e., faster onset of action; no refrigeration needed), we believe that Syndros is well positioned to gain traction in the broader dronabinol market,” Amsellem stated. He also expressed optimism regarding a significant number of physicians who were not prescribing Marinol starting to prescribe Syndros.

Amsellem estimated peak sales of $300M-$400M+ and a long-term EPS CAGR of around 25-30 percent.

Latest Ratings for INSY

Nov 2017JefferiesMaintainsBuy
May 2017PiperJaffrayDowngradesOverweightNeutral
Oct 2016JefferiesMaintainsBuy

View More Analyst Ratings for INSY
View the Latest Analyst Ratings

Posted-In: David Amsellem Piper JaffrayAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (INSY)

View Comments and Join the Discussion!